• UroGen Pharma announced publication of final five-year Olympus follow-up results for Jelmyto on Oct. 28, 2026.
• Results showed durable disease control in adults with low-grade upper tract urothelial cancer who achieved a complete response to treatment.
• No progression to high-grade disease occurred during extended follow-up, supporting Jelmyto’s role as a kidney-sparing treatment option.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854763) on October 28, 2026, and is solely responsible for the information contained therein.